Retina Specialist

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#2113833

United States

#751701

Health/Medicine

#4618

Traffic sources

Monthly visitors

Articles

The year of biosimilars, and list goes well beyond 100

Feb 28, 2025 | retina-specialist.com | Richard Mark Kirkner

Eight Annual Pipeline Report Take-home pointsThese lists consists of 106 investigative programs, including 20 new listings. Nine programs have been dropped since last year because the programs were either discontinued or haven’t reported updated information for more than a year. Five aflibercept biosimilars were approved in 2024, as was a light therapy device.
TikTok on The Clock ...

Aug 21, 2024 | retina-specialist.com | Jayanth Sridhar

BioDr. Sridhar serves as Retina Specialist Magazine’s Social Media Ambassador. He’s an associate professor of clinical ophthalmology at Bascom Palmer Eye Institute, Miami. DISCLOSURE: Dr. Sridhar is a consultant to Alcon, DORC, Genentech/Roche and Regeneron Pharmaceuticals. “...but the party don’t stop.” No, TikTok isn’t referring to the 2009 pop hit by Ke$ha, but rather to one of the most popular social media platforms in the world.
Total Eclipse of the Heart

Jun 13, 2024 | retina-specialist.com | Jayanth Sridhar

BioDr. Sridhar serves as Retina Specialist Magazine’s Social Media Ambassador. He’s an associate professor of clinical ophthalmology at Bascom Palmer Eye Institute, Miami. DISCLOSURE: Dr. Sridhar is a consultant to Alcon, DORC, Genentech/Roche and Regeneron Pharmaceuticals. April 8, 2024 has come and passed. Totality: A total solar eclipse, the last one visible to most of North America until 2045.
What does it mean to be an influencer?

Apr 13, 2024 | retina-specialist.com | Jayanth Sridhar

BioDr. Sridhar serves as Retina Specialist Magazine’s Social Media Ambassador. He’s an associate professor of clinical ophthalmology at Bascom Palmer Eye Institute, Miami. DISCLOSURE: Dr. Sridhar is a consultant to Alcon, DORC, Genentech/Roche and Regeneron Pharmaceuticals.
Hitting the century mark: 100 candidates and counting

Feb 27, 2024 | retina-specialist.com | Richard Mark Kirkner

Seventh Annual Pipeline Report Take-home pointsThis year’s listing includes 100 investigative programs, including 29 new listings. Three high-profile programs from last year exited the list: pegcetacoplan; avacincaptad pegol; and aflibercept 8 mg. Geographic atrophy continues to be a robust area of interest, increasing from 12 to 16 programs despite the exits of two high-profile candidates. Overall, 14 programs from last year’s list don’t appear on this year’s.
The long-term impact of anti-VEGF therapy for DME

Feb 27, 2024 | retina-specialist.com | Lucie Guo |Theodore Leng

Take-home pointsAnti-VEGF medications have been highly effective in clinical trials for improving vision in diabetic macular edema. In real-world settings, patients receive injections less frequently than in clinical trials. Real-world studies have reported smaller gains in vision than clinical trials. Real-world data highlight racial and socioeconomic disparities in the usage and outcome of anti-VEGF therapy.
Managing acute retinal necrosis

Feb 27, 2024 | retina-specialist.com | Dilraj S. Grewal

BiosDr. Grewal is an associate professor of ophthalmology at Duke University. Dr. Thomas is a partner in vitreoretinal surgery and uveitis at Tennessee Retina. DISCLOSURES: Dr. Grewal is a consultant to Iveric Bio, Regeneron, DORC, Alimera and Apellis. Dr. Thomas is a consultant to Allergan/AbbVie, Alimera Sciences, Avesis, EyePoint Pharmaceuticals, Genentech/Roche and Novartis.
An atypical presentation of ocular toxoplasmosis

Feb 27, 2024 | retina-specialist.com | Anthony Obeid

BioDr. Obeid is a first year clinical retina fellow at Wills Eye Hospital, Philadelphia. Dr. Hsu is an attending physician at Mid Atlantic Retina and the Retina Service of Wills Eye Hospital. A 49-year-old female with a past medical history of type 2 diabetes, hypertension and dyslipidemia was referred for evaluation. The patient had been complaining of blurred vision in the left eye for approximately one week.
Be positive, but not too positive

Dec 23, 2023 | retina-specialist.com | Jayanth Sridhar

BioDr. Sridhar serves as Retina Specialist Magazine’s Social Media Ambassador. He’s an associate professor of clinical ophthalmology at Bascom Palmer Eye Institute, Miami. DISCLOSURE: Dr. Sridhar is a consultant to Alcon, DORC, Genentech/Roche and Regeneron Pharmaceuticals. Social media and modern personal electronic devices have transformed the way we interact, learn and share.
The Solow paradox

Dec 23, 2023 | retina-specialist.com | Charles C. Wykoff

Retina specialists are distinctively efficient. We’re used to managing dozens of patients while synthesizing tremendous amounts of data to inform decision-making. Image interpretation is a core strength and a key value we bring to our patients. Most of our optical coherence tomography interpretation is qualitative. Is there fluid? Is there more fluid? Or less? Is the pigment epithelium detachment enlarging? Is the atrophy expanding? This approach appears to be on the edge of a sea-change.